Virotek off of their webpage.Virotek Short-listed for COVID-19 Response Challenge at World Economic Forum Wilmette, IL, July 15, 2020 – Virotek Inc. (or the "Company"), a biotech company focused on the development and commercialization of innovative biological based therapeutics for infectious diseseases announced today that the Company has been short-listed for the World Economic Forums COVID-19 Response Challenge on behalf of Top Tier Impact. The final cohort of up to 15 solutions will be announced at the World Economic Forum's Sustainable Development Summit in September 2020. “We are pleased for this recognition on a global scale and in particular for a cause of such magnitude”. Dr. Saeid Babaei, CEO of Virotek commented. “The world is seeing a crisis of unprecedented nature and effects. Virotek’s team is committed to our mission – to provide innovative and sustainable therapeutic solutions by leveraging our powerful artificial intelligence combined with biologics platform in the fight against COVID-19. The impressive international network of collaborators will allows us to accelerate our COVID-19 development program”. World Economic Forum For 50 years, the World Economic Forum has facilitated public-private cooperation to improve the state of the world, adopting a multistakeholder approach to engage leaders in society. UpLink is a response to this changing world order, and it will enable decision-makers within the Forum’s network to engage more deeply with the creativity, innovation and local knowledge at the grassroots level. UpLink is a platform to crowdsource innovations, in an effort to accelerate the delivery of the UN Sustainable Development Goals (SDGs). About Virotek Inc. Virotek is a privately held US-based biotech company focused on the development and commercialization of innovative therapeutics for unmet medical needs. At Virotek we have taken a unique and alternative approach to drug design and development. By applying fast, accurate and cost-effective methods, we have designed anti-SARS-CoV-2 antibodies and peptides for therapeutic intervention of COVID-19. Our the drug discovery program, based in Ontario, Canada starts with deployment of an advanced Artificial Intelligence, machine and deep learning processes combined with two biological platforms of single-domian antibodies and designer peptides leading to optimal lead drug candidate selection.